DOP2013000270A - Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan - Google Patents

Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan

Info

Publication number
DOP2013000270A
DOP2013000270A DO2013000270A DO2013000270A DOP2013000270A DO P2013000270 A DOP2013000270 A DO P2013000270A DO 2013000270 A DO2013000270 A DO 2013000270A DO 2013000270 A DO2013000270 A DO 2013000270A DO P2013000270 A DOP2013000270 A DO P2013000270A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical compositions
salmonella gallinarum
compositions used
salmonella
modified
Prior art date
Application number
DO2013000270A
Other languages
English (en)
Inventor
Hyang Choi
Soo An Shin
Si Yong Yang
Young Wook Cho
Original Assignee
Cj Cheiljedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corp filed Critical Cj Cheiljedang Corp
Publication of DOP2013000270A publication Critical patent/DOP2013000270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A CEPAS DE SALMONELLA GALLINARUM MODIFICADAS AVIRULENTAS PRODUCIDAS POR INACTIVACIÓN DE AGRUPACIONES DE GENES DE VIRULENCIA DE SALMONELLA GALLINARUM (SG), UN PATÓGENO PRINCIPAL DE LA SALMONELOSIS AVIAR, Y DIVERSOS USOS DE LAS MISMAS, ESPECIALMENTE EN LA PRODUCCIÓN DE BACTERIÓFAGOS LÍTICOS ESPECÍFICOS DE SALMONELLA, COMPOSICIONES FARMACÉUTICAS Y ADITIVOS PARA PIENSOS.
DO2013000270A 2011-05-17 2013-11-15 Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan DOP2013000270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487137P 2011-05-17 2011-05-17
US13/274,854 US8481052B2 (en) 2011-05-17 2011-10-17 Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same

Publications (1)

Publication Number Publication Date
DOP2013000270A true DOP2013000270A (es) 2014-03-31

Family

ID=47175080

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000270A DOP2013000270A (es) 2011-05-17 2013-11-15 Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan

Country Status (10)

Country Link
US (3) US8481052B2 (es)
EP (1) EP2710116B1 (es)
KR (1) KR101500805B1 (es)
CN (2) CN107083351B (es)
BR (1) BR112013029677A2 (es)
CL (2) CL2013003285A1 (es)
DO (1) DOP2013000270A (es)
ES (1) ES2724729T3 (es)
PE (1) PE20141452A1 (es)
WO (1) WO2012157989A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
KR101465605B1 (ko) * 2013-01-25 2014-11-27 강원대학교산학협력단 ssrAB, rpoS 및 hmp 유전자가 결손된 살모넬라 갈리나룸 균주 및 이를 유효성분으로 포함하는 가금 티프스 예방용 백신 조성물
US20170333493A1 (en) * 2014-11-11 2017-11-23 Ohio State Innovation Foundation Probiotic bacteria for the prevention and treatment of salmonella
KR101774863B1 (ko) 2015-07-20 2017-09-05 강원대학교산학협력단 살모넬라증 치료를 위한 변이 균주 ｈｉｄ２０９２와 ｈｉｄ２１１４ 및 이를 포함하는 살모넬라증 약제학적 조성물
WO2017089947A2 (es) 2015-11-25 2017-06-01 Universidad De Los Andes Composición que comprende bacteriófagos para reducir, eliminar y/o prevenir salmonella enteritidis, salmonella typhimurium y salmonella paratyphi b
CN109486714B (zh) * 2018-12-07 2020-08-04 扬州大学 一种鸡伤寒沙门氏菌弱毒分离株及其应用
WO2020205736A1 (en) * 2019-03-29 2020-10-08 Purina Animal Nutrition Llc Bacteriophage animal feed preservative
KR102327091B1 (ko) * 2020-06-18 2021-11-16 전남대학교 산학협력단 암의 치료용 살모넬라 균주 및 이의 용도
CN117480255A (zh) * 2021-04-30 2024-01-30 全南大学校产学协力团 减毒鸡沙门氏菌菌株及其用途
KR20220159913A (ko) * 2021-05-26 2022-12-05 서울대학교산학협력단 살모넬라 갈리나룸 변이균주 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160469C (zh) * 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
KR100436740B1 (ko) * 2003-09-20 2004-06-22 주식회사 인트론바이오테크놀로지 살모넬라 갈리나룸 약독주 및 이를 포함하는 가금티푸스예방용 백신 조성물
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101204584A (zh) * 2007-12-17 2008-06-25 北京娜可长今国际银离子科技开发有限公司 以减毒沙门氏菌为载体的肿瘤疫苗及其制备方法
KR101070938B1 (ko) * 2008-12-02 2011-10-06 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101151532B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101151516B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
WO2011005587A1 (en) * 2009-06-24 2011-01-13 University Of Dubuque Vaccine compositions and methods of use to protect against infectious disease
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same

Also Published As

Publication number Publication date
CN104053768B (zh) 2020-10-30
BR112013029677A2 (pt) 2017-01-24
CL2013003285A1 (es) 2014-06-13
EP2710116A4 (en) 2014-12-24
WO2012157989A2 (en) 2012-11-22
CL2017000232A1 (es) 2017-07-28
KR20120128583A (ko) 2012-11-27
WO2012157989A3 (en) 2013-01-24
CN107083351B (zh) 2021-09-14
US8481052B2 (en) 2013-07-09
ES2724729T3 (es) 2019-09-13
CN104053768A (zh) 2014-09-17
PE20141452A1 (es) 2014-10-23
US20130022574A1 (en) 2013-01-24
US8524243B2 (en) 2013-09-03
US20130202643A1 (en) 2013-08-08
EP2710116B1 (en) 2019-03-27
US9192658B2 (en) 2015-11-24
US20120294892A1 (en) 2012-11-22
KR101500805B1 (ko) 2015-03-09
CN107083351A (zh) 2017-08-22
EP2710116A2 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
DOP2013000270A (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1121129T1 (el) Αναστολεις toy fgfr4 πυριμιδινης
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112016012883A2 (pt) Métodos e composições para aprimorar o rendimento de milho
UY34100A (es) INMUNOCONJUGADOS DEL PROFARMACO seco-MGBA, COMPOSICIONES Y MÉTODOS PARA PREPARARLOS, Y SUS USOS
BR112015004111A2 (pt) novos derivados bicíclicos
EA201500659A1 (ru) Ацетилтрансферазы и их применение для получения каротиноидов
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6990737A2 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR090549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
UY34888A (es) Inhibidores del virus de la hepatitis c
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis